Specific single nucleotide polymorphisms (SNPs) near the interferon lambda-3 (IFNλ3) gene (formerly interleukin 28B) influence the response to treatment with interferon in hepatitis C patients. We aimed to investigate such an influence in hepatitis D patients.
Methods
The study population consisted of hepatitis D patients who were previously treated with pegylated interferon for one year and who were spontaneous clearers of the virus post recent superinfection. The SNP of IFNλ3, rs12979860, was determined by polymerase chain reaction-restriction fragment length polymorphism protocol.
Results
The total number of patients was 64; median age was 30.5 years and 53 were male. The number of patients with sustained virological response 1 year post-treatment was 17, non-responders 29, relapsers 11 and spontaneous clearers post superinfection 7. Cirrhosis was present in 28 (44%). IFNλ3, rs12979860 genotype CC, was present in 41 (64.1%), CT in 21 (32.8%) and TT in 2 (3.1%). There was no difference in the body mass index, baseline alanine aminotransferase, hepatitis B e antigen and HBV DNA status among patients with sustained response and response failure (no response or relapse). The median age of response failures was 33.5 years compared to 26 in responders (P=0.024). They had higher gamma glutamyl transferase levels (P=0.030) and cirrhosis (P=0.003). Genotype CC was present in 29/40 of response failures compared to 9/17 of the responders (P=0.152). Logistic regression analysis showed that cirrhosis was the independent risk factor for failure to have a response (P=0.001). 4/7 patients with spontaneous clearance had genotype CC.
Conclusions
IFNλ3 rs12979860 SNP does not have any significant influence on long-term hepatitis D clearance. Presence of cirrhosis may influence the response.
References
1.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009; 461: 399–401.
2.
ThompsonA.J., MuirA.J., SulkowskiM.S.Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in hepatitis C virus-1 paitents.Gastroenterology2010; 139: 120–129.
3.
GalmozziE., ViganòM., LamperticoP.Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?Aliment Pharmacol Ther2014; 39: 569–578.
4.
BoglioneL., CusatoJ., AllegraS.Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.Antiviral Res2014; 102: 35–43.
5.
AbbasZ., JafriW., RazaS., HepatitisD.Scenario in the Asia-Pacific region.World J Gastroenterol2010; 16: 554–562.
6.
SeetlaniN.K., AbbasZ., RazaS., YakoobJ., JafrisW.Prevalence of hepatitis D in HBsAg positive patients visiting liver clinics.J Pak Med Assoc2009; 59: 434–437.
7.
MumtazK., HamidS.S., AdilS.Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan.J Gastroenterol Hepatol2005; 20: 1503–1507.
AbbasZ., MemonM.S., MithaniH., JafriW., HamidS.Treatment of chronic hepatitis D patients with pegylated interferon: a real world experience.Antivir Ther2014; 19: 463–468.
10.
WedemeyerH., YurdaydìnC., DalekosG.N.Peginterferon plus adefovir versus either drug alone for hepatitis delta.N Engl J Med2011; 364: 322–331.
11.
FabrisC., FalletiE., CussighA.IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.J Hepatol2011; 54: 716–722.
12.
YilmazE., BaranB., SoyerO.M.Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.Clin Gastroenterol Hepatol2014; 12: 1753–1758.
13.
Visco-ComandiniU., LapaD., TaibiC., AngelettiC., CapobianchiM.R., GarbugliaA.R.No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.Dig Liver Dis2014; 46: 348–352.
14.
WitteK., WitteE., SabatR., WolkK.IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties.Cytokine Growth Factor Rev2010; 21: 237–251.
15.
KotenkoS.V., GallagherG., BaurinV.V.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.Nat Immunol2003; 4: 69–77.
16.
SheppardP., KindsvogelW., XuW.IL-28, IL-29 and their class II cytokine receptor IL-28R.Nat Immunol2003; 4: 63–68.
17.
GuedjJ., RotmanY., CotlerS.J.Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.Hepatology2014; 60: 1902–1910.
18.
MoatterT., AbbasZ., ShabirS., JafriW.Clinical presentation and genotype of hepatitis delta in Karachi.World J Gastroenterol2007; 13: 2604–2607.
19.
AbbasZ., MuzaffarR., SiddiquiA., NaqviS.A., RizviS.A.Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi.BMC Gastroenterol2006; 6: 20.
20.
ButiM., HomsM., Rodriguez-FriasF.Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study.J Viral Hepat2011; 18: 434–442.
21.
HeidrichB., YurdaydınC., KabaçamG.Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.Hepatology2014; 60: 87–97.
